Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Market Closed 09-25 16:00:00 EDT

6.95

-0.45

-6.08%

盘后6.95

+0.000.00%

19:37 EDT

High7.18	Low6.73	Vol8.67K
Open7.18	D1 Closing7.40	Amplitude6.05%
Mkt Cap13.12M	Tradable Cap8.98M	Total Shares1.89M
T/O61.01K	T/O Rate0.67%	Tradable Shares1.29M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":6.95,"timestamp":1790366400000,"preClose":7.4,"halted":0,"volume":8674,"hourTrading":{"tag":"盘后","latestPrice":6.95,"preClose":6.95,"latestTime":"19:37 EDT","volume":1874,"amount":13063.6953,"timestamp":1790379477640,"change":0,"changeRate":0,"amplitude":0.007223},"delay":0,"changeRate":-0.060810810810810835,"floatShares":1292320,"shares":1888305,"eps":-8.73186,"marketStatus":"Market Closed","change":-0.45,"latestTime":"09-25 16:00:00 EDT","open":7.18,"high":7.18,"low":6.7325,"amount":61013.9369298,"amplitude":0.060473,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.73186,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":7.4,"postHourTrading":{"tag":"盘后","latestPrice":6.95,"preClose":6.95,"latestTime":"19:37 EDT","volume":1874,"amount":13063.6953,"timestamp":1790379477640,"change":0,"changeRate":0,"amplitude":0.007223},"volumeRatio":0.7234120720336111},"requestUrl":"/m/hq/s/NRSN/wiki","defaultTab":"wiki","newsList":[{"id":"2670424180","title":"Press Release: NeuroSense Provides Business Update and Progress for the First Half of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424180","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424180?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:30","pubTimestamp":1790368200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Sept. 25, 2026 /PRNewswire/ -- Therapeutics Ltd.  , a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today provided a business update with corporate highlights to date and financial results for the first half of 2026.NeuroSense is advancing PrimeC, its investigational combination therapy for amyotrophic lateral sclerosis , through regulatory pathways in the United States and Canada while pursuing a focused, capital-efficient late-stage development strategy.\"Our focus remains on advancing PrimeC toward the next stage of development and, ultimately, toward patients,\" said Alon Ben-Noon, Chief Executive Officer of NeuroSense. \"We are working diligently to move our development plans forward in a capital-efficient manner, while pursuing the regulatory, clinical, financing and strategic opportunities available to us. Looking ahead, our priorities include advancing our regulatory pathway in Canada,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4139","LU2065732104.USD","BK4097","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667650145","title":"NASDAQ Trade Halt Continues Reason not Available at 06:55 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2667650145","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667650145?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:55","pubTimestamp":1789383300,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUESREASON NOT AVAILABLE AT 06:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nAQN2MJ4TJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577710","title":"Neurosense Therapeutics Ltd trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577710","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577710?lang=en_us&edition=fundamental","pubTime":"2026-09-12 07:50","pubTimestamp":1789170612,"startTime":"0","endTime":"0","summary":"19:50 EDT Neurosense (NRSN) Therapeutics Ltd trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-therapeutics-ltd-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-therapeutics-ltd-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666357728","title":"NASDAQ Trade Halt Halt News Pending at 07:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2666357728","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666357728?lang=en_us&edition=fundamental","pubTime":"2026-09-12 07:50","pubTimestamp":1789170600,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:50 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nAQN2MJ0LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666759637","title":"NeuroSense Therapeutics to Present at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666759637","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666759637?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:04","pubTimestamp":1789045468,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics to present at H.C. Wainwright Global Investment ConferenceNeuroSense will attend the H.C. Wainwright 28th Annual Global Investment Conference in New York City on Sept. 14-16, 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDL3l7GDt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666530192","title":"Neurosense Therapeutics Ltd: to Effect Reverse Share Split of Co’s Ordinary Shares at Ratio of 1-for-20","url":"https://stock-news.laohu8.com/highlight/detail?id=2666530192","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666530192?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:41","pubTimestamp":1788986492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN4510M6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305725","title":"NeuroSense Therapeutics Effects 1-for-20 Reverse Stock Split on Sept. 14, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305725","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305725?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:31","pubTimestamp":1788985861,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics effects 1-for-20 reverse stock split on Sept. 14, 2026NeuroSense Therapeutics will execute a 1-for-20 reverse stock split of its ordinary shares.Post-split trading on the Nasda","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL6wHmFm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664487503","title":"NeuroSense Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664487503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664487503?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:28","pubTimestamp":1788431280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRSN/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NRSN","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875302","title":"Neurosense Therapeutics Ltd. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664875302?lang=en_us&edition=fundamental","pubTime":"2026-09-03 18:04","pubTimestamp":1788429850,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nAZN4TI5GE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663005531","title":"NeuroSense announces redesigned development plan for PrimeC","url":"https://stock-news.laohu8.com/highlight/detail?id=2663005531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663005531?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:55","pubTimestamp":1788180943,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced a redesigned development plan for PrimeC in amyotrophic lateral sclerosis, structured to reach a potential...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-announces-redesigned-development-plan-for-primec-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-announces-redesigned-development-plan-for-primec-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600375","title":"NeuroSense Targets Faster, Lower-Cost ALS Approval Path for PrimeC Under Revamped Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600375?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:45","pubTimestamp":1788180356,"startTime":"0","endTime":"0","summary":"NeuroSense targets faster, lower-cost ALS approval path for PrimeC under revamped development planNeuroSense outlined an accelerated, lower-cost development plan to move PrimeC toward a potential ALS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL4T5KLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663755003","title":"NeuroSense Plans Head-to-Head PrimeC Trial Versus Mitsubishi Tanabe’s Edaravone in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2663755003","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663755003?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:45","pubTimestamp":1788180331,"startTime":"0","endTime":"0","summary":"NeuroSense plans head-to-head PrimeC trial versus Mitsubishi Tanabe’s edaravone in ALSNeuroSense outlined a redesigned development plan for PrimeC in ALS, aiming to speed a regulatory filing while cut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL8CzGkh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663003735","title":"Neurosense Unveils Accelerated, Capital-Efficient Strategy to Advance Primec Toward Potential Approval in ALS","url":"https://stock-news.laohu8.com/highlight/detail?id=2663003735","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663003735?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:45","pubTimestamp":1788180300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nTUA1WYPLN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662384420","title":"NeuroSense Therapeutics Shareholders Authorized Board to Pursue Reverse Stock Split Range 1-for-4 to 1-for-40","url":"https://stock-news.laohu8.com/highlight/detail?id=2662384420","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662384420?lang=en_us&edition=fundamental","pubTime":"2026-08-28 04:16","pubTimestamp":1787861775,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics shareholders authorized board to pursue reverse stock split range 1-for-4 to 1-for-40NeuroSense Therapeutics held a special shareholder meeting on Aug. 26, 2026.Shareholders au","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL2ns8Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659506111","title":"NeuroSense Announces Shareholder Letter Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2659506111","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659506111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:36","pubTimestamp":1786628198,"startTime":"0","endTime":"0","summary":"NeuroSense announces shareholder letter availabilityNeuroSense Therapeutics released a CEO letter to shareholders outlining near-term priorities for PrimeC in ALS.FDA clearance received to start the P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1jwkbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659505181","title":"NeuroSense Targets December 2026 Canada Filing for PrimeC ALS Drug Amid Phase 3 Paragon Preparations","url":"https://stock-news.laohu8.com/highlight/detail?id=2659505181","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659505181?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:31","pubTimestamp":1786627898,"startTime":"0","endTime":"0","summary":"NeuroSense targets December 2026 Canada filing for PrimeC ALS drug amid Phase 3 PARAGON preparationsNeuroSense set plans to launch the Phase 3 PARAGON trial of PrimeC in ALS, targeting about 300 parti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL5gxNSB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658911286","title":"Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN) and Brookdale Senior Living (BKD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658911286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658911286?lang=en_us&edition=fundamental","pubTime":"2026-08-11 23:40","pubTimestamp":1786462847,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurosense Therapeutics Ltd. (NRSN) and Brookdale Se...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-and-brookdale-senior-living-bkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-neurosense-therapeutics-ltd-nrsn-and-brookdale-senior-living-bkd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","NRSN","BK4185","BKD","BK4581","LU2190626999.HKD","LU0029874061.USD","BK4585","LU0842063009.USD","XLV","LABU","LU0128526141.USD","LU1499592464.USD","BK4588","BK4139","HCSG","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657865378","title":"NeuroSense sees December 2026 as filing date for NDS for PrimeC","url":"https://stock-news.laohu8.com/highlight/detail?id=2657865378","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657865378?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:35","pubTimestamp":1786030550,"startTime":"0","endTime":"0","summary":"NeuroSense (NRSN) Therapeutics announced that it is targeting December 2026 for the filing of a New Drug Submission with Health Canada for PrimeC, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neurosense-sees-december-2026-as-filing-date-for-nds-for-primec-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neurosense-sees-december-2026-as-filing-date-for-nds-for-primec-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656991253","title":"NeuroSense Therapeutics Announces Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2656991253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656991253?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:17","pubTimestamp":1785529029,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics announces special shareholder meetingNeuroSense Therapeutics will hold a special shareholder meeting in Ra’anana, Israel on Aug. 26, 2026.Shareholders will vote on authorizing ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL7D2jht:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399194","title":"NeuroSense Amends JonesTrading Equity Distribution Agreement for up to $3.79 Million Share Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399194","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399194?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:16","pubTimestamp":1785529007,"startTime":"0","endTime":"0","summary":"NeuroSense amends JonesTrading equity distribution agreement for up to $3.79 million share salesNeuroSense amended its JonesTrading Capital on Demand sales agreement to align it with a new Form F-3 re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL4jWWF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":0.0945},{"period":"1month","weight":-0.1504},{"period":"3month","weight":-0.5412},{"period":"6month","weight":-0.5246},{"period":"1year","weight":-0.7055},{"period":"ytd","weight":-0.5481}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.184296},{"month":3,"riseRate":0.4,"avgChangeRate":0.030043},{"month":4,"riseRate":0.6,"avgChangeRate":-0.103871},{"month":5,"riseRate":0.4,"avgChangeRate":-0.003304},{"month":6,"riseRate":0.6,"avgChangeRate":0.298631},{"month":7,"riseRate":0,"avgChangeRate":-0.259476},{"month":8,"riseRate":0.4,"avgChangeRate":-0.11133},{"month":9,"riseRate":0.4,"avgChangeRate":0.018774},{"month":10,"riseRate":0,"avgChangeRate":-0.14429},{"month":11,"riseRate":0.75,"avgChangeRate":0.430569},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction